blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3166636

EP3166636 - PSGL-1 MODULATORS AND USES THEREOF [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  11.11.2022
Database last updated on 02.11.2024
FormerThe patent has been granted
Status updated on  05.03.2021
FormerGrant of patent is intended
Status updated on  19.10.2020
FormerExamination is in progress
Status updated on  12.10.2018
FormerRequest for examination was made
Status updated on  18.04.2017
FormerThe international publication has been made
Status updated on  03.02.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024  [2024/41]
Applicant(s)For all designated states
Sanford-Burnham Medical Research Institute
10901 North Torrey Pines Road
La Jolla, CA 92037 / US
[2017/20]
Inventor(s)01 / BRADLEY, Linda, M.
10901 North Torrey Pines Road
La Jolla, CA 92037 / US
02 / TINOCO, Roberto
10901 North Torrey Pines Road
La Jolla, CA 92037 / US
 [2017/20]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2021/14]
Former [2017/20]Cripps, Joanna Elizabeth, et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date15819318.508.07.2015
[2017/20]
WO2015US39586
Priority number, dateUS201462022191P08.07.2014         Original published format: US 201462022191 P
[2017/20]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2016007653
Date:14.01.2016
Language:EN
[2016/02]
Type: A2 Application without search report 
No.:EP3166636
Date:17.05.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 14.01.2016 takes the place of the publication of the European patent application.
[2017/20]
Type: B1 Patent specification 
No.:EP3166636
Date:07.04.2021
Language:EN
[2021/14]
Search report(s)International search report - published on:US07.04.2016
(Supplementary) European search report - dispatched on:EP30.01.2018
ClassificationIPC:A61K39/395, C07K16/00, A61K48/00, C07K14/705, // C07K16/28, A61K39/00
[2018/09]
CPC:
A61P1/04 (EP); C07K16/2854 (US); A61P17/06 (EP);
A61P19/02 (EP); A61P21/00 (EP); A61P25/00 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P31/00 (EP);
A61P31/04 (EP); A61P31/06 (EP); A61P31/08 (EP);
A61P31/14 (EP); A61P31/16 (EP); A61P31/18 (EP);
A61P31/20 (EP); A61P31/22 (EP); A61P33/06 (EP);
A61P33/14 (EP); A61P35/00 (EP); A61P35/02 (EP);
A61P37/02 (EP); A61P37/06 (EP); A61P39/02 (EP);
A61P9/00 (EP); C07K14/70596 (EP,US); C07K16/2896 (EP,US);
A61K2039/505 (EP,US); A61K48/00 (EP,US); C07K2317/76 (EP,US);
Y02A50/30 (EP) (-)
Former IPC [2017/20]A61K39/395, C07K16/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/20]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:PSGL-1-MODULATOREN UND VERWENDUNGEN DAVON[2017/20]
English:PSGL-1 MODULATORS AND USES THEREOF[2017/20]
French:MODULATEURS PSGL-1 ET LEURS UTILISATIONS[2017/20]
Entry into regional phase03.02.2017National basic fee paid 
03.02.2017Search fee paid 
03.02.2017Designation fee(s) paid 
03.02.2017Examination fee paid 
Examination procedure03.02.2017Examination requested  [2017/20]
03.02.2017Date on which the examining division has become responsible
23.08.2018Amendment by applicant (claims and/or description)
16.10.2018Despatch of a communication from the examining division (Time limit: M06)
24.04.2019Reply to a communication from the examining division
12.07.2019Despatch of a communication from the examining division (Time limit: M06)
21.01.2020Reply to a communication from the examining division
20.10.2020Communication of intention to grant the patent
25.02.2021Fee for grant paid
25.02.2021Fee for publishing/printing paid
25.02.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21155316.9  / EP3881863
EP22163107.0  / EP4079324
Opposition(s)Opponent(s)01  06.01.2022  11.01.2022  ADMISSIBLE
Regimbeau Sarl
20 rue de Chazelles
75847 Paris Cedex 17 / FR
Opponent's representative
Regimbeau
20, rue de Chazelles
75847 Paris Cedex 17 / FR
 [2022/07]
21.01.2022Invitation to proprietor to file observations on the notice of opposition
29.07.2022Despatch of communication that the patent will be revoked
08.08.2022Legal effect of revocation of patent [2022/50]
Fees paidRenewal fee
25.07.2017Renewal fee patent year 03
27.08.2018Renewal fee patent year 04
29.07.2019Renewal fee patent year 05
27.07.2020Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.07.201804   M06   Fee paid on   27.08.2018
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.07.2015
AL07.04.2021
AT07.04.2021
CY07.04.2021
CZ07.04.2021
DK07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
MK07.04.2021
MT07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SE07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
LU08.07.2021
CH31.07.2021
LI31.07.2021
IS07.08.2021
[2024/41]
Former [2024/22]HU08.07.2015
AL07.04.2021
AT07.04.2021
CY07.04.2021
CZ07.04.2021
DK07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
MK07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SE07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
LU08.07.2021
CH31.07.2021
LI31.07.2021
IS07.08.2021
Former [2024/18]HU08.07.2015
AL07.04.2021
AT07.04.2021
CY07.04.2021
CZ07.04.2021
DK07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SE07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
LU08.07.2021
CH31.07.2021
LI31.07.2021
IS07.08.2021
Former [2023/30]AL07.04.2021
AT07.04.2021
CY07.04.2021
CZ07.04.2021
DK07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SE07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
LU08.07.2021
CH31.07.2021
LI31.07.2021
IS07.08.2021
Former [2022/29]AL07.04.2021
AT07.04.2021
CZ07.04.2021
DK07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SE07.04.2021
SI07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
LU08.07.2021
CH31.07.2021
LI31.07.2021
IS07.08.2021
Former [2022/26]AL07.04.2021
AT07.04.2021
CZ07.04.2021
DK07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SE07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
LU08.07.2021
CH31.07.2021
LI31.07.2021
IS07.08.2021
Former [2022/23]AT07.04.2021
CZ07.04.2021
DK07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SE07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
LU08.07.2021
CH31.07.2021
LI31.07.2021
IS07.08.2021
Former [2022/21]AT07.04.2021
CZ07.04.2021
DK07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SE07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
CH31.07.2021
LI31.07.2021
IS22.12.2021
Former [2022/18]AT07.04.2021
CZ07.04.2021
DK07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
MC07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SE07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS22.12.2021
Former [2022/10]AT07.04.2021
CZ07.04.2021
DK07.04.2021
EE07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SE07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS22.12.2021
Former [2022/09]AT07.04.2021
CZ07.04.2021
DK07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RO07.04.2021
RS07.04.2021
SE07.04.2021
SK07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
Former [2022/08]AT07.04.2021
CZ07.04.2021
DK07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RS07.04.2021
SE07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
Former [2022/07]AT07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RS07.04.2021
SE07.04.2021
SM07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
Former [2021/52]AT07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
PL07.04.2021
RS07.04.2021
SE07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
Former [2021/51]AT07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
RS07.04.2021
SE07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
IS07.08.2021
Former [2021/49]AT07.04.2021
FI07.04.2021
HR07.04.2021
LT07.04.2021
LV07.04.2021
SE07.04.2021
BG07.07.2021
NO07.07.2021
GR08.07.2021
Former [2021/47]AT07.04.2021
FI07.04.2021
LT07.04.2021
BG07.07.2021
Former [2021/46]AT07.04.2021
FI07.04.2021
LT07.04.2021
Documents cited:Search[I]US2005152906  (LEVANON AVIGDOR [IL], et al) [I] 1-6,8-11,13-15 * [0175],[0176] and claims 2, 26, 27 *;
 [I]  - S. ZHANG ET AL, "Targeting CD162 protects against streptococcal M1 protein-evoked neutrophil recruitment and lung injury", AMERICAN JOURNAL OF PHYSIOLOGY - LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, US, (20131115), vol. 305, no. 10, doi:10.1152/ajplung.00220.2013, ISSN 1040-0605, pages 756 - 763, XP055414695 [I] 1-3,5-11,13-15 * Results and Discussion *

DOI:   http://dx.doi.org/10.1152/ajplung.00220.2013
 [A]  - SAORI UMEKI ET AL, "Characterization of monoclonal antibodies against canine P-selectin glycoprotein ligand-1 (PSGL-1)", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, ELSEVIER BV, AMSTERDAM, NL, vol. 142, no. 1, doi:10.1016/J.VETIMM.2011.04.009, ISSN 0165-2427, (20110413), pages 119 - 125, (20110421), XP028227886 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.vetimm.2011.04.009
 [T]  - TINOCO ROBERTO ET AL, "PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion", IMMUNITY, CELL PRESS, US, (20160517), vol. 44, no. 5, doi:10.1016/J.IMMUNI.2016.04.015, ISSN 1074-7613, pages 1190 - 1203, XP029537981 [T] 1-15

DOI:   http://dx.doi.org/10.1016/j.immuni.2016.04.015
 [I]  - C. TRIPODO ET AL, "P-Selectin Glycoprotein Ligand-1 as a Potential Target for Humoral Immunotherapy of Multiple Myeloma (Supplementry Material)", CURRENT CANCER DRUG TARGETS, NL, (20090801), vol. 9, no. 5, doi:10.2174/156800909789056971, ISSN 1568-0096, pages 617 - 625, XP055414720 [I] 1-3,5-15 * Results and Discussion *

DOI:   http://dx.doi.org/10.2174/156800909789056971
 [A]  - A. HOOS ET AL, "Metastatic Growth Progression Caused by PSGL-1-Mediated Recruitment of Monocytes to Metastatic Sites", CANCER RESEARCH, US, (20140201), vol. 74, no. 3, doi:10.1158/0008-5472.CAN-13-0946, ISSN 0008-5472, pages 695 - 704, XP055414668 [A] 1-15 * Discussion *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-13-0946
 [A]  - TOSHIFUMI YAMAOKA ET AL, "The roles of P- and E-selectins and P-selectin glycoprotein ligand-1 in primary and metastatic mouse melanomas", JOURNAL OF DERMATOLOGICAL SCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 64, no. 2, doi:10.1016/J.JDERMSCI.2011.07.005, ISSN 0923-1811, (20110726), pages 99 - 107, (20110805), XP028301978 [A] 1-15

DOI:   http://dx.doi.org/10.1016/j.jdermsci.2011.07.005
International search[Y]US2002058034  (MANJUNATH NARASIMHASWAMY [US], et al) [Y] 11, 24, 35 * . Especially para [0029]. *;
 [XY]US2009304709  (LIN RONG-HWA [TW], et al) [X] 1-3, 5-7, 9, 10, 19-23, 30- 34 * . Especially para [0006], [0007], [0009], [0025], [0034], [0074], [0078], [0108] * [Y] 4, 8, 11-18, 24-29, 35-40;
 [Y]US2012014979  (DENT ALEXANDER [US]) [Y] 16, 28, 39 * . Especially para [0005] *;
 [Y]  - NISHIMURA et al., Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71., (20090700), vol. 15, no. 7, pages 794 - 797, XP 055383041 [Y] 4, 12, 18 * . Especially abstract, pg 794 col 2 para 2, pg 797 col 1 para 3. *
 [Y]  - SWERS et al., "A high affinity human antibody antagonist of P-selectin mediated rolling.", Biochem Biophys Res Comm, (20061124), vol. 350, no. 3, doi:doi:10.1016/j.bbrc.2006.08.197, pages 508 - 513, XP 024924671 [Y] 8 * . Especially abstract, pg 508 col 2 para 1. *
 [Y]  - URZAINQUI et al., "Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells.", J Immunol, (20071201), vol. 179, no. 11, pages 7457 - 7465, XP 055383047 [Y] 13, 14, 25, 26, 36, 37 * . Especially abstract. *
 [Y]  - AUSTIN et al., "The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH 1 effector populations: a type 1 differentiation bias is also measured in circulating blood T c", J Invest Dermatol, (19991100), vol. 113, no. 5, pages 752 - 759, XP055383547 [Y] 15, 27, 38 * . Especially abstract. *

DOI:   http://dx.doi.org/10.1046/j.1523-1747.1999.00749.x
 [Y]  - LORD et al., "T-bet is required for optimal proinflammatory CD 4+ T- cell trafficking.", Blood, (20051115), vol. 106, no. 10, doi:doi:10.1182/BLOOD-2005-04-1393, pages 3432 - 3439, XP 002523816 [Y] 17, 29, 40 * . Especially pg 3438 col 2 para 2. *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.